How to explore Scott Alexander's work and his 1500+ blog posts? This unaffiliated fan website lets you sort and search through the whole codex. Enjoy!

See also Top Posts and All Tags.

Minutes:
Blog:
Year:
4622 tags
Show all filters
2 posts found
Dec 22, 2021
acx

Addendum To Luvox Post

4 min • 432 words • 39 comments • 97 likes • podcast (5 min)
Scott provides updates on efforts to get FDA approval for fluvoxamine as a COVID-19 treatment and reports on the early approval of Paxlovid. Longer summary
This post is an addendum to a previous article about Luvox and COVID-19 treatment. It updates readers on recent developments in the effort to get FDA approval for fluvoxamine (Luvox) as a COVID-19 treatment. Scott reports that Dr. Ed Mills and colleagues have found a way to submit an Emergency Use Authorization (EUA) application to the FDA for fluvoxamine, despite the initial hurdle of not having a sponsoring drug company. The post also mentions the FDA's approval of Paxlovid, another COVID-19 drug, which happened earlier than expected according to prediction markets. Shorter summary
Scott Alexander argues that doctors should prescribe fluvoxamine for COVID-19 despite FDA inaction, urging them to overcome discomfort with off-label use when evidence supports it. Longer summary
Scott Alexander discusses the use of fluvoxamine (Luvox) as a potential treatment for COVID-19. He argues that despite strong evidence from clinical trials showing its effectiveness, many doctors are hesitant to prescribe it due to it being off-label use. The FDA has not added COVID-19 to the drug's label, citing bureaucratic issues. Scott criticizes this inaction and suggests that doctors should be willing to prescribe off-label when evidence supports it, even if it feels uncomfortable. He relates personal experiences of hesitating to prescribe off-label medications due to social pressure and encourages doctors to critically examine their reasons for not prescribing fluvoxamine for COVID-19. Shorter summary